John Rex, MD, FACP, discusses the promise, precision, and challenges of this first-in-class antifungal following phase 2b trial results.
John Rex, MD, FACP
Advertisement
Chief Medical Officer at F2G
Articles by John Rex, MD, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
First Confirmed Death From Meat Allergy Spread by Lone Star Ticks
2
US Hospital Safety Rankings Unveiled
3
Single-Tablet HIV Combination Therapy Demonstrates Noninferiority When Switched From Multitablet Regimens
4
One Health System's Evolution in the Rise in Dalbavancin Prescribing for Off-Label Indications
5
